Analysts Issue Forecasts for PMN FY2026 Earnings

Promis Neurosciences (NASDAQ:PMN – Free Report) – Stock analysts at Brookline Capital Markets raised their FY2026 earnings per share estimates for Promis Neurosciences in a research report issued to clients and investors on Friday, November 13th. Brookline Capital Markets analyst F. Ahmed now anticipates that the company will post earnings per share of ($4.93) for the year, up from their previous estimate of ($5.21). The consensus estimate for Promis Neurosciences’ current full-year earnings is ($4.82) per share. Brookline Capital Markets also issued estimates for Promis Neurosciences’ Q4 2026 earnings at ($1.47) EPS, Q1 2027 earnings at ($1.88) EPS, Q2 2027 earnings at ($1.46) EPS, Q3 2027 earnings at ($1.58) EPS and FY2027 earnings at ($6.69) EPS.

Promis Neurosciences (NASDAQ:PMN – Get Free Report) last issued its earnings results on Thursday, November 12th. The company reported ($0.89) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.28) by $0.39.

PMN has been the subject of a number of other reports. Guggenheim reaffirmed a “buy” rating and set a $69.00 price objective (up from $35.00) on shares of Promis Neurosciences in a report on Tuesday, July 28th. HC Wainwright reiterated a “buy” rating on shares of Promis Neurosciences in a research report on Monday, October 12th. Weiss Ratings downgraded shares of Promis Neurosciences from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday. Wall Street Zen raised shares of Promis Neurosciences from a “sell” rating to a “hold” rating in a report on Saturday. Finally, Roth Capital dropped their target price on shares of Promis Neurosciences to $15.00 and set a “buy” rating for the company in a research report on Monday, November 2nd. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $30.50.

Get Our Latest Stock Report on PMN

Promis Neurosciences Price Performance

NASDAQ PMN opened at $3.21 on Wednesday. Promis Neurosciences has a 12 month low of $2.78 and a 12 month high of $27.40. The stock’s 50 day moving average is $8.80 and its 200 day moving average is $12.52.

Institutional Trading of Promis Neurosciences

A number of large investors have recently added to or reduced their stakes in the company. Janus Henderson Group PLC purchased a new stake in shares of Promis Neurosciences during the 1st quarter worth approximately $16,418,000. Ally Bridge Group NY LLC boosted its position in shares of Promis Neurosciences by 66.1% during the 1st quarter. Ally Bridge Group NY LLC now owns 414,219 shares of the company’s stock valued at $5,261,000 after acquiring an additional 164,880 shares during the last quarter. Yu Fan bought a new position in shares of Promis Neurosciences during the 1st quarter valued at approximately $4,188,000. ADAR1 Capital Management LLC bought a new position in shares of Promis Neurosciences during the 1st quarter valued at approximately $1,211,000. Finally, Seven Fleet Capital Management LP purchased a new position in shares of Promis Neurosciences in the first quarter valued at $135,000. Institutional investors own 50.13% of the company’s stock.

Insider Activity

In other news, Director Eugene Williams bought 26,500 shares of Promis Neurosciences stock in a transaction dated Wednesday, November 4th. The shares were purchased at an average cost of $3.43 per share, with a total value of $90,895.00. Following the completion of the acquisition, the director owned 40,213 shares of the company’s stock, valued at $137,930.59. This trade represents a 193.25% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Neil Cashman bought 10,000 shares of the firm’s stock in a transaction that occurred on Monday, November 2nd. The stock was purchased at an average price of $3.86 per share, for a total transaction of $38,600.00. Following the completion of the transaction, the insider directly owned 14,532 shares of the company’s stock, valued at $56,093.52. This represents a 220.65% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders bought 37,816 shares of company stock worth $134,746 over the last ninety days. Insiders own 1.50% of the company’s stock.

About Promis Neurosciences

(Get Free Report)

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company developing antibody-based treatments for neurodegenerative diseases. Its research focuses on misfolded proteins that may contribute to these conditions. The company’s technology is designed to identify disease-associated forms of proteins while distinguishing them from their normally functioning counterparts. Its lead program, PMN310, is an antibody candidate targeting toxic amyloid-beta oligomers for the potential treatment of Alzheimer’s disease.

Read More

Earnings History and Estimates for Promis Neurosciences (NASDAQ:PMN)

Receive News & Ratings for Promis Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Promis Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.